Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 161 results for infarction

  1. Myocardial infarction: measurement of ejection fraction (IND75)

    This indicator covers the proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG94

  2. Myocardial infarction: coronary reperfusion (IND72)

    This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG91

  3. Endovascular stent insertion for intracranial atherosclerotic disease (HTG288)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  4. Myocardial infarction: PCI rates (IND74)

    This indicator covers the time between call for help and balloon inflation for patients with ST segment elevation myocardial infarction (STEMI) undergoing reperfusion by primary percutaneous coronary intervention (PCI). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG93

  5. Microwave ablation of hepatocellular carcinoma (HTG138)

    Evidence-based recommendations on microwave ablation of hepatocellular carcinoma. This involves using heat from microwave energy to destroy the cancer cells.

  6. Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (HTG266)

    Evidence-based recommendations on thoracoscopic exclusion of the left atrial appendage in atrial fibrillation (with or without other cardiac surgery) for the prevention of thromboembolism. This involves inserting a camera and instruments through small cuts in the chest and closing the left atrial appendage.

  7. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  8. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  9. Myocardial infarction: PCI in less than 60 minutes (IND73)

    This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous coronary intervention (PCI) in less than 60 minutes from time of admission at a centre with primary PCI facilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG92

  10. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  11. Myocardial infarction: medication for MI in preceding 12 months (IND125)

    This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79

  12. Myocardial infarction: medication for MI more than 12 months ago (IND126)

    This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80

  13. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

  14. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  15. Laparoscopic gastric plication for the treatment of severe obesity (HTG293)

    Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.